Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 68Recurrence 17Neoplasms 5Immunoglobulin Light-chain Amyloidosis 5Neoplasms, Plasma Cell 4Lymphoma, Large B-Cell, Diffuse 3Renal Insufficiency 2Plasmacytoma 2Myeloproliferative Disorders 2Chromosome 17 deletion 2Amyloidosis 2Thrombocytosis 1Smoldering Multiple Myeloma 1Sarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Paraproteinemias 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1

Interventions

Cyclophosphamide 9Rituximab 6Tacrolimus 5Busulfan 5fludarabine phosphate 4blinatumomab 4Vincristine 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4fludarabine 3Whole-Body Irradiation 3Valganciclovir 3Everolimus 3venetoclax 2dacetuzumab 2cobomarsen 2Thiotepa 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Filgrastim 2Epoetin Alfa 2Antilymphocyte Serum 2sargramostim 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Lymphoproliferative Disorders × pomalidomide × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡